ALS (Motor Neurone Disease): cell-therapy evidence and registered trials

Registry snapshot

ClinicalTrials.gov returned 65 registered studies for the stored condition/intervention query, including 10 recruiting records, retrieved 2026-08-05T06:02:03+00:00. A registry count does not establish efficacy, approval, relevance or eligibility; inspect each study's design, product, status and inclusion criteria.

• Open the stored ClinicalTrials.gov query
• Open the recruiting-study query

Research activity over time

Registration of new studies accelerated: 19 newly registered studies in 2021–2025 against 14 in 2016–2020. The first study in this registry query was posted in 2008; the registry now holds 65 in total, of which 10 are recruiting. Counting is by first-posted date, so the series reflects when research was registered — not enrolment, completion or results.

Source: ClinicalTrials.gov API v2, retrieved 2026-08-05. A registration count is not evidence of efficacy, approval or eligibility. Open the exact query ↗

What to verify before interpreting a study or offer

1. The exact product, cell source, processing, dose and delivery route.
2. The indication, study phase, comparator, endpoints, status and eligibility criteria.
3. Whether the proposed use is authorised, part of a registered trial or otherwise investigational.
4. Provider and manufacturing authorisations, release testing, traceability and adverse-event reporting.
5. How the proposal compares with current standard care, reviewed by an independent physician.

Sources & further reading

• Stem-cell trials registry (ClinicalTrials.gov) ↗
• Peer-reviewed research (PubMed) ↗
• ISSCR — patient resources ↗
• FDA — consumer guidance ↗
• EMA — ATMP framework ↗

Registry data is a discovery aid, not evidence that a treatment works or is suitable for an individual patient.